According to the recent WHO statistics, outdoor pollution has risen by 8% in the last five years. This data has been compiled from 3000 major cities and towns around the world. So, what does that mean? Does it mean the air we are breathing is no longer safe? Yes, the air that is supposed to keep us alive is in fact slowly killing us. Unfortunately, populations in low-income cities are the most impacted. The pollutants in the air are not just pollutants but are the vectors of various life-threatening diseases like Lung Cancer.
According to WHO, air pollution is killing more people today, more than HIV/AIDS. The major factors in play are increased urbanization, population and also the increase in number of vehicles. The number of vehicles around the world is expected to reach 2 billion soon. According to the recent revelation, 98 percent of the cities in low and medium income countries do not meet the WHO specified guidelines for air quality. But, in the high-income countries, the percent is close to 58. As urban air quality declines, the risk of stroke, heart disease, and chronic and acute respiratory diseases, asthma and Lung Cancer which is the deadliest of all.
It is one of the leading cause of death in both men and women. According to statistics, 1 out of 4 cancer patients is suffering from lung cancer. On an average it takes more lives than colon, breast and prostate cancer combined. Decreased air quality and increased air pollution is just one of the major causes of this cancer. Smoking is still one of the major causes of lung cancer. Smoking is not only dangerous for the one who smoke but also to the passive smokers, who unknowingly inhale the toxic smoke. The Suspended Particulate Matter or PM for short is the component of air that is harmful. PM2.5 is the particles that are of 2.5 micron and are very harmful while PM10 are those of 10 microns which are not so harmful. Nonetheless, polluted air is still harmful, especially to children and elders.
Lung cancer is a malignant tumor regarded as uninhibited growth of cell tissues in the lung. Lung cancer declines the lung capability to deliver oxygen to bloodstream. Some of the key indications of lung cancer comprise of appetite loss, wheezing, weight loss, coughing, bloody mucus, shortness of breath, and chest pain. Due to the rapid advancement in technology, lung cancer is now brought down to its knees and it’s not that deadly anymore.
Today lung cancer can be treated in many methods ranging from Chemotherapy to Radiotherapy and also various other therapeutic treatment methods. Lung Cancer Chemotherapy drug type includes cisplatin, taxol, navelbine, camptosar and Alimta. Lung Cancer Radiotherapy is segregated into external beam, internal beam and systemic beam. Other Lung Cancer Therapeutic Drugs are segmented into abraxane, avastin, crizotinib, docetaxel and Gefitinib.
Increase in the pollution and increase in the smoking population at such a rapid pace, it is fueling the growth of Lung Cancer Therapeutics Market. Research analysts at Market Data Forecast estimated the market at $5.65 billion in 2016 and projected to be growing at a CAGR of 6.7%, to reach $7.81 billion by 2021.
Additionally, introduction of superior priced drugs and new advanced radiation therapies have boosted the market. New product expansion, contracts and associations and procurements are some of the significant approaches adopted by the prominent players like Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis. in the lung cancer therapeutics market. North America and Europe leads the global lung cancer therapeutics market. But due to increased pollution in China and India, Asia-Pacific Market is expected to have fastest growth.
Want to know more about this market? Don’t wait and get the Market Research Report by Market Data Forecast on Lung Cancer Therapeutics Market. Grab a Free Research Sample now. To get all the latest updates on Healthcare Industry, follow our blog and subscribe to our Newsletter.